Cabozantinib in ovarian clear cell cancers: UnMET expectations.
Publication
, Journal Article
Secord, AA; Previs, RA; Nixon, AB
Published in: Gynecol Oncol
July 2018
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Gynecol Oncol
DOI
EISSN
1095-6859
Publication Date
July 2018
Volume
150
Issue
1
Start / End Page
1 / 2
Location
United States
Related Subject Headings
- Receptor Protein-Tyrosine Kinases
- Pyridines
- Ovarian Neoplasms
- Oncology & Carcinogenesis
- Humans
- Female
- Anilides
- Adenocarcinoma, Clear Cell
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Secord, A. A., Previs, R. A., & Nixon, A. B. (2018). Cabozantinib in ovarian clear cell cancers: UnMET expectations. Gynecol Oncol, 150(1), 1–2. https://doi.org/10.1016/j.ygyno.2018.06.006
Secord, Angeles Alvarez, Rebecca A. Previs, and Andrew B. Nixon. “Cabozantinib in ovarian clear cell cancers: UnMET expectations.” Gynecol Oncol 150, no. 1 (July 2018): 1–2. https://doi.org/10.1016/j.ygyno.2018.06.006.
Secord AA, Previs RA, Nixon AB. Cabozantinib in ovarian clear cell cancers: UnMET expectations. Gynecol Oncol. 2018 Jul;150(1):1–2.
Secord, Angeles Alvarez, et al. “Cabozantinib in ovarian clear cell cancers: UnMET expectations.” Gynecol Oncol, vol. 150, no. 1, July 2018, pp. 1–2. Pubmed, doi:10.1016/j.ygyno.2018.06.006.
Secord AA, Previs RA, Nixon AB. Cabozantinib in ovarian clear cell cancers: UnMET expectations. Gynecol Oncol. 2018 Jul;150(1):1–2.
Published In
Gynecol Oncol
DOI
EISSN
1095-6859
Publication Date
July 2018
Volume
150
Issue
1
Start / End Page
1 / 2
Location
United States
Related Subject Headings
- Receptor Protein-Tyrosine Kinases
- Pyridines
- Ovarian Neoplasms
- Oncology & Carcinogenesis
- Humans
- Female
- Anilides
- Adenocarcinoma, Clear Cell
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis